A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 201–300 of 3,965
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00165-x · Cited by 152
Self-citationCostabel, U., Miyazaki, Y., Pardo, A., Koschel, D., Bonella, F., Spagnolo, P., Guzman, J., Ryerson, C. J., & Selman, M. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0191-z · Cited by 181
Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-139 · Cited by 151
Costabel, U., Albera, C., Lancaster, L. H., Lin, C.-Y., Hormel, P., Hulter, H. N., & Noble, P. W. (2017) · Respiration · doi:10.1159/000479976 · Cited by 150
Self-citationCombination therapy: the future of management for idiopathic pulmonary fibrosis?
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70232-2 · Cited by 150
Strategies for Achieving Healthy Vascular Aging
Nowak, K. L., Rossman, M. J., Chonchol, M., & Seals, D. R. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10439 · Cited by 151
Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 148
Mechanisms of Lung Fibrosis Resolution
Glasser, S. W., Hagood, J. S., Wong, S. S., Taype, C. A., Madala, S. K., & Hardie, W. D. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.018 · Cited by 160
Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling
Parichatikanond, W., Luangmonkong, T., Mangmool, S., & Kurose, H. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00034 · Cited by 175
Zinellu, A., Collu, C., Nasser, M., Paliogiannis, P., Mellino, S., Zinellu, E., Traclet, J., Ahmad, K., Mangoni, A. A., Carru, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184134 · Cited by 196
Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Liu, Y.-M., Nepali, K., & Liou, J.-P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00935 · Cited by 147
Povedano, J. M., Martinez, P., Serrano, R., Tejera, Á., Gómez-López, G., Bobadilla, M., Flores, J. M., Bosch, F., & Blasco, M. A. (2018) · eLife · doi:10.7554/elife.31299 · Cited by 139
Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., Wells, A., Wuyts, W., Koschel, D., Kreuter, M., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30044-3 · Cited by 146
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
Bonella, F., Wijsenbeek, M., Molina-Molina, M., Duck, A., Mele, R., Geissler, K., & Wuyts, W. (2016) · European Respiratory Journal · doi:10.1183/13993003.01204-2015 · Cited by 144
Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
Li, L., & Kan, L. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.12.042 · Cited by 160
“Recently, a new drug pirfenidone has been approved for clinical use, however, it has only been able to slow the progression of the disease with unproven safety of long-term use (King et al., 2014; Lancaster et al., 2016).”
BackgroundRisk factors for diagnostic delay in idiopathic pulmonary fibrosis
Hoyer, N., Prior, T. S., Bendstrup, E. M., Wilcke, T., & Shaker, S. B. (2019) · Respiratory Research · doi:10.1186/s12931-019-1076-0 · Cited by 175
Developments in lung transplantation over the past decade
van der Mark, S. C., Hoek, R. A. S., & Hellemons, M. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0132-2019 · Cited by 167
Raghu, G., Pellegrini, C. A., Yow, E., Flaherty, K. R., Meyer, K., Noth, I., Scholand, M. B., Cello, J., Ho, L. A., Pipavath, S., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30301-1 · Cited by 144
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Spagnolo, P., Ryerson, C. J., Putman, R. K., Oldham, J. M., Salisbury, M. L., Sverzellati, N., Valenzuela, C., Guler, S. A., Jones, S., Wijsenbeek, M. S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00017-5 · Cited by 164
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 161
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Lukey, P. T., Harrison, S. A., Yang, S., Man, Y., Holman, B. F., Rashidnasab, A., Azzopardi, G., Grayer, M., Simpson, J. K., Bareille, P., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01992-2018 · Cited by 143
“It is worth noting that AEs related to the gastro-intestinal tract are observed in IPF subjects treated with pirfenidone [3] and nintedanib [2].”
BackgroundRole and New Insights of Pirfenidone in Fibrotic Diseases
Mora, D. A. L.-D. L., Sanchez-Roque, C., Montoya-Buelna, M., Sanchez-Enriquez, S., Lucano-Landeros, S., Macias-Barragan, J., & Armendariz-Borunda, J. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11579 · Cited by 142
Jablonski, R. P., Kim, S., Cheresh, P., Williams, D. B., Morales‐Nebreda, L., Cheng, Y., Yeldandi, A., Bhorade, S., Pardo, A., Selman, M., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201601077r · Cited by 142
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Flaherty, K. R., Fell, C. D., Huggins, J. T., Nunes, H., Sussman, R., Valenzuela, C., Petzinger, U., Stauffer, J. L., Gilberg, F., Bengus, M., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00230-2018 · Cited by 141
Self-citationKim, S. Y., Diggans, J., Pankratz, D., Huang, J., Pagan, M., Sindy, N., Tom, E., Anderson, J. D., Choi, Y., Lynch, D. A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00140-x · Cited by 149
Self-citationLehmann, M., Buhl, L., Alsafadi, H. N., Klee, S., Hermann, S., Mutze, K., Ota, C., Lindner, M., Behr, J., Hilgendorff, A., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0876-y · Cited by 138
Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes
Sauleda, J., Núñez, B., Sala, E., & Soriano, J. B. (2018) · Medical Sciences · doi:10.3390/medsci6040110 · Cited by 137
“Nintedanib, a tyrosine kinase inhibitor that targets growth factor pathways, and pirfenidone, a pleiotropic drug with anti-inflammatory and antifibrotic effects, slow the rate of forced vital capacity (FVC) decline by approximately 50% over the course of one year [51,52] and have shown a reduction in mortality [53,54].”
BackgroundFibrotic microtissue array to predict anti-fibrosis drug efficacy
Asmani, M., Velumani, S., Li, Y., Wawrzyniak, N., Hsia, I., Chen, Z., Hinz, B., & Zhao, R. (2018) · Nature Communications · doi:10.1038/s41467-018-04336-z · Cited by 137
Salisbury, M. L., Lynch, D. A., van Beek, E. J. R., Kazerooni, E. A., Guo, J., Xia, M., Murray, S., Anstrom, K. J., Yow, E., Martinez, F. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1385oc · Cited by 136
“(25-27) With change in FVC adopted as the primary endpoint in recent clinical trials, AMFMmeasurement of GGR at baseline may prove a useful, automated tool, particularly for cohort enrichment likely to improve power when change in FVC is the primary endpoint.(28-34) Prior studies utilized different methodology in a re…”
Ghebremariam, Y. T., Cooke, J. P., Gerhart, W., Griego, C., Brower, J., Doyle‐Eisele, M., Moeller, B. C., Zhou, Q., Ho, L. A., de Andrade, J. A., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0614-x · Cited by 147
“Recently FDA approved drugs, pirfenidone and nintedanib, only slow the disease progression [5, 6] and development of more effective therapies are hampered by an incomplete understanding of the factors involved in the disease pathogenesis.”
BackgroundAntifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Collins, B. F., & Raghu, G. (2019) · European Respiratory Review · doi:10.1183/16000617.0022-2019 · Cited by 134
AMPK orchestrates an elaborate cascade protecting tissue from fibrosis and aging
Jiang, S., Li, T. X., Yang, Z. P., Yi, W., Di, S., Sun, Y., Wang, D., & Yang, Y. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.07.001 · Cited by 141
NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis
Tian, R., Zhu, Y., Yao, J., Meng, X., Wang, J., Xie, H., & Wang, R. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.028 · Cited by 134
Behr, J., Nathan, S. D., Wuyts, W. A., Mogulkoc Bishop, N., Bouros, D. E., Antoniou, K., Guiot, J., Kramer, M. R., Kirchgaessler, K.-U., Bengus, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30356-8 · Cited by 134
Self-citationFrom ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Michalski, J. E., Kurche, J. S., & Schwartz, D. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.09.001 · Cited by 145
Wu, J., Song, D., Li, Z., Guo, B., Xiao, Y., Liu, W., Liang, L., Feng, C., Gao, T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0354-1 · Cited by 133
“Importantly, there are still no effective FDA-approved drugs to treat ALI, ARDS or IPF hitherto, and most experimental drugs are still in the midst of Phase II or Phase III clinical studies.(2,9,10)”
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Estornut, C., Milara, J., Bayarri, M. A., Belhadj, N., & Cortijo, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794997 · Cited by 161
“This trial confirmed that PFD reduces disease progression, as improved lung function, exercise tolerance, and progression-free survival (King et al., 2014) (ClinicalTrials.”
BackgroundLancaster, L., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., King, T. E., et al. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000105 · Cited by 132
Self-citationHexokinase 2 couples glycolysis with the profibrotic actions of TGF-β
Yin, X., Choudhury, M., Kang, J. H., Schaefbauer, K. J., Jung, M.-Y., Andrianifahanana, M., Hernandez, D. M., & Leof, E. B. (2019) · Science Signaling · doi:10.1126/scisignal.aax4067 · Cited by 143
John, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18397-6 · Cited by 131
Ying, H., Fang, M., Hang, Q. Q., Chen, Y., Qian, X., & Chen, M. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16821 · Cited by 131
Therapeutic targets in idiopathic pulmonary fibrosis
Kolb, M. R. J., Bonella, F., & Wollin, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.062 · Cited by 142
Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial
Moor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Chavannes, N. H., & Wijsenbeek, M. S. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0328oc · Cited by 147
Dysregulation of metabolic pathways in pulmonary fibrosis
Rajesh, R., Atallah, R., & Bärnthaler, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108436 · Cited by 139
A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis
Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0784oc · Cited by 129
Self-citationMesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review
Srour, N., & Thébaud, B. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0121 · Cited by 136
Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment
Kaur, A., Mathai, S. K., & Schwartz, D. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00154 · Cited by 129
Kafaja, S., Clements, P. J., Wilhalme, H. M., Tseng, C., Furst, D. E., Kim, G. H. J., Goldin, J. G., Volkmann, E. R., Roth, M. D., Tashkin, D. P., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1845oc · Cited by 135
Lin, H., & Jiang, S. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.04.17 · Cited by 142
Molecular imaging of fibrosis: recent advances and future directions
Montesi, S. B., Désogère, P., Fuchs, B. C., & Caravan, P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122132 · Cited by 127
“In IPF, recently conducted clinical trials have used change in forced vital capacity at 52 weeks as the primary outcome (6, 7).”
BackgroundMethodComorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0044-2019 · Cited by 139
Cottin, V., & Maher, T. (2015) · European Respiratory Review · doi:10.1183/09059180.00011514 · Cited by 126
Fan, M.-H., Zhu, Q., Li, H., Ra, H.-J., Majumdar, S., Gulick, D. L., Jerome, J. A., Madsen, D. H., Christofidou‐Solomidou, M., Speicher, D. W., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.701433 · Cited by 134
West Japan Oncology Group, Iwata, T., Yoshino, I., Yoshida, S., Ikeda, N., Tsuboi, M., Asato, Y., Katakami, N., Sakamoto, K., Yamashita, Y., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0398-4 · Cited by 125
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
van der Velden, J. L. J., Ye, Y., Nolin, J. D., Hoffman, S. M., Chapman, D. G., Lahue, K. G., Abdalla, S., Chen, P., Liu, Y., Bennett, B., et al. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0117-2 · Cited by 125
Rajala, K., Lehto, J. T., Sutinen, E., Kautiainen, H., Myllärniemi, M., & Saarto, T. H. (2017) · ERJ Open Research · doi:10.1183/23120541.00084-2017 · Cited by 148
Pérez-Bogerd, S., Wuyts, W. A., Barbier, V., Demeyer, H., Muylem, A. V., Janssens, W., & Troosters, T. (2018) · Respiratory Research · doi:10.1186/s12931-018-0884-y · Cited by 143
Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis
Kropski, J. A., & Blackwell, T. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041317-102715 · Cited by 137
Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1020-3 · Cited by 125
Self-citationIdiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis
Brown, S.-A. W., Dobelle, M., Padilla, M. L., Agovino, M., Wisnivesky, J. P., Hashim, D., & Boffetta, P. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201807-481oc · Cited by 149
Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis
Mahalanobish, S., Saha, S., Dutta, S., & Sil, P. C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104591 · Cited by 147
Lee, T.-H., Yeh, C., Lee, Y.-T., Shih, Y.-C., Chen, Y.-T., Hung, C., You, M.-Y., Wu, P., Shentu, T., Huang, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18047-x · Cited by 137
Mahler, D. A., & O'Donnell, D. E. (2015) · Chest · doi:10.1378/chest.14-0800 · Cited by 105
Lung Manifestations in the Rheumatic Diseases
Doyle, T. J., & Dellaripa, P. F. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.05.015 · Cited by 133
Song, X., Bai, S., He, N., Wang, R., Xing, Y., Lv, C., & Yu, F. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02519 · Cited by 125
Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., et al. (2017) · Respirology · doi:10.1111/resp.12989 · Cited by 123
Self-citationShi, J., Li, F., Luo, M., Wei, J., & Liu, X. (2017) · Mediators of Inflammation · doi:10.1155/2017/3520581 · Cited by 137
Idiopathic pulmonary fibrosis: An update
Spagnolo, P., Sverzellati, N., Rossi, G., Cavazza, A., Tzouvelekis, A., Crestani, B., & Vancheri, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.982165 · Cited by 120
Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., López-Otín, C., & Pardo, A. (2016) · European Respiratory Journal · doi:10.1183/13993003.00398-2016 · Cited by 122
Zhang, Y., Lu, W., Zhang, X., Lü, J., Xu, S., Chen, S., Zhong, Z., Zhou, T., Wang, Q., Chen, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104307 · Cited by 129
Acharya, N., Sharma, S., Mishra, D., Dhooria, S., Dhir, V., & Jain, S. (2020) · Rheumatology International · doi:10.1007/s00296-020-04565-w · Cited by 133
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Cottin, V., Koschel, D., Günther, A., Albera, C., Azuma, A., Sköld, C. M., Tomassetti, S., Hormel, P., Stauffer, J. L., Strombom, I., et al. (2018) · ERJ Open Research · doi:10.1183/23120541.00084-2018 · Cited by 121
Zhang, C., Wu, Z., Li, J., Tan, K., Yang, W., Zhao, H., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26634 · Cited by 131
Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Zheng, Q., Cox, I. A., Campbell, J. A., Xia, Q., Otáhal, P., de Graaff, B., Corte, T. J., Teoh, A. K. Y., Walters, E. H., & Palmer, A. J. (2022) · ERJ Open Research · doi:10.1183/23120541.00591-2021 · Cited by 149
Dinnon, K. H., Leist, S. R., Okuda, K., Dang, H., Fritch, E. J., Gully, K. L., la Cruz, G. D., Evangelista, M. D., Asakura, T., Gilmore, R. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5070 · Cited by 150
Cigarette Smoke-Induced Respiratory Response: Insights into Cellular Processes and Biomarkers
Cha, S.-R., Jang, J., Park, S., Ryu, S. M., Cho, S.-J., & Yang, S. (2023) · Antioxidants · doi:10.3390/antiox12061210 · Cited by 164
Behr, J., Neuser, P., Prasse, A., Kreuter, M., Rabe, K., Schade-Brittinger, C., Wagner, J., & Günther, A. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0462-y · Cited by 120
Reducing protein oxidation reverses lung fibrosis
Anathy, V., Lahue, K. G., Chapman, D. G., Chia, S. B., Casey, D. T., Aboushousha, R., van der Velden, J. L. J., Elko, E., Hoffman, S. M., McMillan, D. H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0090-y · Cited by 120
Lung transplantation: indications and contraindications
Weill, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.141 · Cited by 137
Cecchini, M. J., Hosein, K., Howlett, C. J., JOSEPH, M. G., & Mura, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0857-1 · Cited by 141
“Patients with NSIP will often have a good response to corticosteroids, while IPF can worsen on prednisone [6], and is currently treated with anti-fibrotic agents [7, 8].”
BackgroundJapanese guideline for the treatment of idiopathic pulmonary fibrosis
Homma, S. A., Bando, M., Azuma, A., Sakamoto, S., Sugino, K., Ishii, Y., Izumi, S., Inase, N., Inoue, Y., Ebina, M., et al. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.003 · Cited by 135
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., Kasselman, L. J., Glass, A. D., DeLeon, J. R., & Reiss, A. B. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.04.002 · Cited by 140
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Liu, G. Y., Budinger, G. R. S., & Dematte, J. E. (2022) · BMJ · doi:10.1136/bmj-2021-066354 · Cited by 145
Wuyts, W. A., Kolb, M., Stowasser, S., Stansen, W., Huggins, J. T., & Raghu, G. (2016) · Lung · doi:10.1007/s00408-016-9912-1 · Cited by 119
TGFβ, smooth muscle cells and coronary artery disease: a review
Low, E. L., Baker, A. H., & Bradshaw, A. C. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.09.004 · Cited by 134
Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial
Brody, S. L., Gunsten, S. P., Luehmann, H. P., Sultan, D. H., Hoelscher, M., Heo, G. S., Pan, J., Koenitzer, J. R., Lee, E. C., Huang, T., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1132oc · Cited by 126
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 128
Clinical impact of the interstitial lung disease multidisciplinary service
Jo, H. E., Glaspole, I., Levin, K., McCormack, S. R., Mahar, A. M., Cooper, W. A., Cameron, R., Ellis, S. J., Cottee, A. M., Webster, S. E., et al. (2016) · Respirology · doi:10.1111/resp.12850 · Cited by 123
Self-citationPulmonary Fibrosis in Hermansky–Pudlak Syndrome
Vicary, G. W., Vergne, Y., Santiago-Cornier, A., Young, L. R., & Roman, J. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201603-186fr · Cited by 140
Tissue remodelling in pulmonary fibrosis
Knudsen, L., Ruppert, C., & Ochs, M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2543-2 · Cited by 129
The Future of Lung Transplantation
Young, K. A., & Dilling, D. F. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1036 · Cited by 140
Myllärniemi, M., & Kaarteenaho, R. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26385 · Cited by 117
Mediavilla-Varela, M., Boateng, K., Noyes, D., & Antonia, S. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2162-z · Cited by 118
Ahmadi, Z., Wysham, N. G., Lundström, S., Janson, C., Currow, D. C., & Ekström, M. P. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207439 · Cited by 121
Optimizing quality of life in patients with idiopathic pulmonary fibrosis
van Manen, M. J. G., Geelhoed, J. J. M., Tak, N. C., & Wijsenbeek, M. S. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816686743 · Cited by 124
Knipe, R. S., Probst, C. K., Lagares, D., Franklin, A., Spinney, J. J., Brazee, P. L., Grasberger, P., Zhang, L., Black, K. E., Sakai, N., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0075oc · Cited by 117
Collard, H. R., Chen, S.-Y., Yeh, W.-S., Li, Q., Lee, Y.-C., Wang, A., & Raghu, G. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201412-553oc · Cited by 116
Immune mechanisms in fibrotic interstitial lung disease
Kamiya, M., Carter, H. M., Espíndola, M. S., Doyle, T. J., Lee, J. S., Merriam, L. T., Zhang, F., Kawano-Dourado, L. B., Sparks, J. A., Hogaboam, C. M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.015 · Cited by 141
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.